SMP3124LP

Sumitomo Pharma America, Inc. · Phase 1 active Small molecule

At a glance

Generic name	SMP3124LP
Sponsor	Sumitomo Pharma America, Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

SMP-3124LP in Adults With Advanced Solid Tumors (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

SMP3124LP CI brief — competitive landscape report
SMP3124LP updates RSS · CI watch RSS
Sumitomo Pharma America, Inc. portfolio CI